Repligen corp stock.

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 18.68% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Repligen Corp (RGEN) to unravel why momentum evaluation plays a crucial role in making savvy investment choices. We also examine how to measure ...Repligen Corporation share price live 164.94, this page displays NASDAQ RGEN stock exchange data. View the RGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Repligen Corporation real time stock price chart below. You can ...Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.

Oct 13, 2023 · Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.

On average, Wall Street analysts predict. that Repligen's share price could reach $188.75 by Nov 2, 2024. The average Repligen stock price prediction forecasts a potential upside of 25.33% from the current RGEN share price of $150.60.Find the latest Repligen Corp (RGN.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.

Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.77% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.8. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Dimensional Fund Advisors LP raised its position in Repligen Co. (NASDAQ:RGEN – Free Report) by 8.2% during the 2nd quarter, HoldingsChannel.com …The stock’s lowest price was $157.58 before closing at $157.00. Repligen Corp. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $200.98 on 02/16/23, while the lowest price for the same period was registered at $110.45 on 10/30/23.

Nov 7, 2023 · Repligen Corp Stock Price History. Repligen Corp’s price is currently up 12.18% so far this month. During the month of November, Repligen Corp’s stock price has reached a high of $152.22 and a low of $126.86. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $110.45. Year to date, Repligen Corp’s stock is ...

Repligen ( RGEN) is the IBD Stock of the Day on a breakout Thursday as the maker of products used in coronavirus vaccine development posted better-than-expected earnings and raised its outlook ...

Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract ...Avantor Inc does not currently pay a dividend. Currently, Repligen Corp’s price-earnings ratio is 63.2. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Analysts expect adjusted earnings to reach $1.748 per share for the current fiscal ...Learn more about whether ICU Medical Inc or Repligen Corp is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics. ... AAII Growth Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00.

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Learn more about whether ICU Medical Inc or Repligen Corp is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics. ... AAII Growth Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.Track Repligen Corp. (RGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information.On November 1, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN had a median target of $190.00, with a high estimate of $210.00 and a low estimate of $148.00. This median estimate represents a significant increase of …Dec 1, 2023 · View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue €801.54M. Net Income €185.96M. 2022 Sales Growth 19.54%. Employees 2,025.

× Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGEFeb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%. Detailed statistics for Repligen Corporation (RGEN) stock, including valuation metrics, financial numbers, share information and more.Apr 28, 2023 · Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36. The share price of Repligen Corp. (NASDAQ:RGEN) dipped -2.38% to close Friday’s market session at $119.58, lower as compared to yesterday’s close. The stock price fluctuated between $118.08 and $122.45 throughout the trading session with the volume trading being 788849 shares, which represented a significant variation when …Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing. 4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Raising target price to $161.00REPLIGEN CORP has an ... Nov. 14, 2023 ...

305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

Repligen Corp stock has a Value Score of 5, Growth Score of 82 and Momentum Score of 69. Comparing AmerisourceBergen Corp. and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well …

However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ...View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for ...RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.As of February 22, 2023, Repligen Corp had a $9.9 billion market capitalization, compared to the Medical Equipment, Supplies & Distribution median of $330.1 million. Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 5.92% in the past year. Currently, Repligen Corp’s price-earnings ratio is 58.8.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing ...Feb 28, 2023 · Repligen Corp’s trailing 12-month revenue is $801.5 million with a 23.2% net profit margin. Year-over-year quarterly sales growth most recently was 0.2%. Analysts expect adjusted earnings to reach $2.678 per share for the current fiscal year. Repligen Corp does not currently pay a dividend. How We Compare DexCom, Inc. and Repligen Corp Stock ... Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions. ... Raising target price to $161.00REPLIGEN CORP has an ... Nov. 14, 2023 ...UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Repligen Corp stock has a Growth Score of 82, Estimate Revisions Score of 38 and Quality Score of 71. Comparing Abbott Laboratories and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as …

Repligen Corp (RGEN-1.40%) Q3 ... 10 stocks we like better than Repligen When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for ...Successfully navigating the dynamic landscape of stock investing requires an understanding of factors like momentum to judge a stock’s price trend. In this article, we take an in-depth look at Repligen Corp (RGEN) to unravel why momentum evaluation plays a crucial role in making savvy investment choices. We also examine how to measure ...Detailed statistics for Repligen Corporation (RGEN) stock, including valuation metrics, financial numbers, share information and more.Discover historical prices for RGEN stock on Yahoo Finance. View daily, weekly or monthly format back to when Repligen Corporation stock was issued.Instagram:https://instagram. murf stockbest fha lenders in indianabest international real estate appcrypto trading robot Waltham, Massachusetts 02453. Phone 1 781 250-0111. Industry Biotechnology. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023. Revenue $801.54M. Net Income $185.96M. 2022 Sales Growth 19.54%. gold mining stocks listgoog stock split The United States Marines traces its roots back to 1776, and it’s the oldest military institution in the country. When Marines earn distinction during their service, the Marine Corps recognizes this service with a variety of medals and ribb...Quotes Summary Real-Time Live After-Hours Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the … crsb Repligen Corp’s ( RGEN) price is currently down 7.18% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $159.54. Over the last year, Repligen Corp has hit prices as high as $235.06 and as low as $134.64. Year to date, Repligen Corp’s stock is down 39.05%.Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not.